about
Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug actionThe prevalence of sexually transmitted infections in Papua New Guinea: a systematic review and meta-analysis.Impact of male circumcision on the HIV epidemic in Papua New Guinea: a country with extensive foreskin cutting practices.In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Dynamics of hepatitis B virus clearance in chimpanzees.The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiologySignificant reduction in HIV prevalence according to male circumcision intervention in sub-Saharan Africa.Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusionModelling the Impact of Cell-To-Cell Transmission in Hepatitis B Virus.Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission.Differentiating founder and chronic HIV envelope sequences.Kinetics of acute hepatitis B virus infection in humans.Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success.HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.High prevalence and incidence of HIV, sexually transmissible infections and penile foreskin cutting among sexual health clinic attendees in Papua New Guinea.A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection.The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future.Minimal impact of circumcision on HIV acquisition in men who have sex with men.Dynamics of in vivo hepatitis D virus infection.Roadmap to control HBV and HDV epidemics in China.Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication.Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.Variability in long-term hepatitis B virus dynamics under antiviral therapy.Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.In silico single cell dynamics of hepatitis B virus infection and clearance.Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.Mathematical modelling of the impact of haematopoietic stem cell-delivered gene therapy for HIV.T-lymphocyte perturbation following large-scale apheresis and hematopoietic stem cell transplantation in HIV-infected individuals.HIV dynamics linked to memory CD4+ T cell homeostasis.Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.Modelling hepatitis C virus infection and the development of hepatocellular carcinoma.Increasing HIV diagnoses in Australia among men who have sex with men correlated with the growing number not taking antiretroviral therapy.
P50
Q28489076-6B698F45-DB66-4B37-9BDF-7F2C53902849Q33784515-5DABC3F5-2E09-4215-B061-AEA35D9AFC2CQ34027755-79246FFA-E93B-48CC-829F-1BC79A4240D1Q34221633-8C9AF152-8283-4F65-ACC8-89EBF1BCC487Q34298630-F5761921-D76F-495E-83A1-F8D2F6DFE7B7Q34338519-A6262333-BAC7-451D-A0CD-60BC1BD85810Q34757746-2A955C96-183F-4DA6-9CEA-98B2D78602CBQ34806845-54F35724-C608-4747-B140-01B061E8EEEDQ35191116-D1CDD964-5EF8-4C8A-AB73-2E668E1E0E57Q35274822-86C9C35E-F5E2-4004-ABBE-9D6654C95EE3Q36066951-EB61D59F-4EB9-415C-8C81-B8D7CA71137CQ36113029-A2F7E1BB-21C0-4336-9C27-B92661CB7DF2Q36164165-72EBA7F9-58F5-448D-A656-F9CF51E6E908Q36277153-93467B69-7CA1-4E55-9968-D7F6D2AE3088Q36369106-5518B7D8-B0D5-4E75-AC19-74BC8093EC23Q37359256-3FEDFB4F-959F-4610-A587-63400B9A09B2Q37401812-828F28E0-76CC-4641-A50D-49DC89821125Q37417692-CD77B957-2AF1-4BE6-8F0C-CF93354E173BQ37643783-915B2C56-F918-435E-9658-C7F4E6123ADAQ37844752-2DE6B925-E988-4D25-AA93-D3A7D6A50BA8Q39352449-B546F616-DA39-4089-AF70-94C26AF26E57Q39681384-C0E5BE13-51CA-45B2-9845-624027AC3115Q39818910-B67F20A8-0077-4240-BC21-0348A14DEAFEQ39890725-DA4E19F3-28DE-4F4C-B0BD-1A2A57EB438AQ40228350-7D85168E-F7B5-43F0-A121-3EBBE16322AAQ40552088-1AA52C25-8802-4209-A0B8-4FD18A15D119Q40679543-D9D71578-50DE-4E48-A832-398D5B4971A8Q40841454-68969D17-F653-4656-8FD5-DF9483DE3F1EQ40848116-F00A6ECF-83BD-4967-8F7F-8B894BDA443BQ41456104-D8B294D0-37C3-4DE0-9423-EA73DA72B366Q41616486-A0B821A4-8513-44A5-85BA-0ED8B3CFE241Q42988476-F2785A41-E0A2-48BF-B7DC-F79763541698Q42996717-7F9296DB-AA72-4651-8E5E-518D827F2745Q43040685-C493C79A-FD74-492E-9863-3C094D7A8A0FQ43577202-9A26CEE6-8F0E-4482-8F83-E83B2503BA56Q44179746-655DD0EA-E6A7-4743-AA2B-D60BE01A435CQ44555364-DABF4361-B695-4C4F-AAE1-2C8F32CE6BCCQ44790341-4BDA0127-35F6-48E0-B3F4-9A24FFD9D8FAQ45357733-528E457F-B19C-45FD-ACEF-7974CE3EDAD4Q45718079-C613598A-1D12-429E-98A9-6B992FA7FAFE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John M. Murray
@ast
John M. Murray
@en
John M. Murray
@es
John M. Murray
@nl
John M. Murray
@sl
type
label
John M. Murray
@ast
John M. Murray
@en
John M. Murray
@es
John M. Murray
@nl
John M. Murray
@sl
prefLabel
John M. Murray
@ast
John M. Murray
@en
John M. Murray
@es
John M. Murray
@nl
John M. Murray
@sl
P1053
B-5481-2009
P106
P1153
7404760150
P21
P2456
P31
P3829
P496
0000-0001-9314-2283